PRESS RELEASE:
Local middle Georgia surgeon, Dr. Johnny Gayton of Eyesight Associates, spoke about the approval of Bromday during the October annual meeting of the Academy of American Ophthalmology held in Chicago. Bromday 0.09% (bromfenac ophthalmic solution) is a once-daily ophthalmic nonsteroidal anti-inflammatory drug (NSAID) manufactured by Ista Pharmaceuticals, Inc. The prescription eye drop recently received FDA approval for the treatment of post operative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. Bromday is approved for once a day dosing beginning 1 day before cataract surgery, on the day of surgery, and continuing for the first 14 days after surgery although many doctors use it longer. “It offers excellent potency and excellent penetration, and the rate at which is goes from outside the cornea to the anterior chamber is very rapid,” Dr. Gayton said. “Bromday can be used once a day, and, in our studies and my clinical experience and the clinical experience of many eye surgeons, Bromday is just as effective as Xibrom.” Bromday was re-labeled from Xibrom, the company’s previous leading twice-daily NSAID, which has a well-established record of safety. Bromday is believed to help patients undergoing cataract surgery with convenience and compliance by using a once a day drop. Ista said that it expects to launch Bromday by the end of this year. Twice-daily Xibrom will be discontinued in early 2011. Johnny L. Gayton, MD, is a clinical investigator, speaker, and consultant to Ista Pharmaceuticals, Inc. His practice, Eyesight Associates is located at 216 Corder Road in Warner Robins, GA.